Rochester General Health System is, effective immediately and until further notice, suspending the use of power morcellation in gynecologic surgeries, including hysterectomies.
The Food and Drug Administration (FDA) has issued an advisory stating that the use of power morcellation in some surgeries may spread cancer.
Morcellation is a technique used in minimally invasive/robotic uterine surgery that uses a power tool to cut tissue while still in the body so it can be removed through the smaller incisions.
“Upon review of the FDA communication, RGHS is suspending use of the power morcellator until further notice,” said Eugene Toy MD, Chief, OB-GYN/RGHS. “A formal policy regarding the use of morcellation in gynecologic surgery will be established next month during a special meeting of the GYN OR committee.”
Dr. Toy says that patients scheduled to have surgery with the use of power morcellation will be counseled on this policy change and offered alternative surgical options in the meantime.
Friday, November 30, 2018
Rochester Regional Health has announced that its wholly-owned subsidiary, ACM Global Laboratories, has hired Brian Wright to lead ACM Global.Read News Article
Thursday, November 29, 2018
For the third time, Rochester General Hospital has received accreditation from the Surgical Review Corp as a Center of Excellence in Minimally Invasive Gynecology (COEMIG).Read News Article